Details for Patent: 11,370,755
✉ Email this page to a colleague
Which drugs does patent 11,370,755 protect, and when does it expire?
Patent 11,370,755 protects DAYBUE STIX and DAYBUE and is included in two NDAs.
Protection for DAYBUE STIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixteen patent family members in fifteen countries.
Summary for Patent: 11,370,755
| Title: | Compositions of trofinetide |
| Abstract: | This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders. |
| Inventor(s): | Clive Blower, Mathew Peterson, James Murray Shaw, James Anthony Bonnar, Etienne David Frank Philippe Moniotte, Martin Bernard Catherine Bousmanne, Cecilia Betti, Karel Willy Luc Decroos, Mimoun Ayoub |
| Assignee: | NEUREN PHARMACEUTICALS Ltd , Neuren Pharmaceuticals Ltd New Zealand |
| Application Number: | US17/347,135 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 11,370,755
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharms Inc | DAYBUE STIX | trofinetide | FOR SOLUTION;ORAL | 219884-001 | Dec 11, 2025 | RX | Yes | Yes | 11,370,755*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Acadia Pharms Inc | DAYBUE STIX | trofinetide | FOR SOLUTION;ORAL | 219884-002 | Dec 11, 2025 | RX | Yes | Yes | 11,370,755*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Acadia Pharms Inc | DAYBUE STIX | trofinetide | FOR SOLUTION;ORAL | 219884-003 | Dec 11, 2025 | RX | Yes | Yes | 11,370,755*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,370,755
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020324396 | ⤷ Start Trial | |||
| Brazil | 112022002229 | ⤷ Start Trial | |||
| Canada | 3149633 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
